Eli Lilly (NYSE: LLY) has entered a collaboration agreement with fellow U.S. firm Fauna Bio to explore novel anti-obesity drug targets, marking a significant step in the competitive weight-loss therapies market. The financial terms of the deal include an undisclosed upfront payment, potential sales royalties, and up to $494 million in milestone payments.
This partnership will utilize Fauna’s AI platform to analyze the genetic adaptations of hibernating mammals, including the 13-lined ground squirrel, tenrecs, and spiny mice. Fauna’s extensive database currently includes thousands of transcriptomes, proteomes, and epigenomes, providing a rich resource for drug discovery.- Flcube.com
